Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 29c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.38 --0%
Revenue Growth %: +5.9%
Financial Fact:
Loss per share - basic and diluted: -0.05
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +5.9%
Financial Fact:
Loss per share - basic and diluted: -0.05
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.68, $0.29 better than the analyst estimate of $0.39. Revenue for the quarter came in at $146.54 million versus the consensus estimate of $140.22 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $560.7 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- SPS Commerce (SPSC) 400 contracts of July 60 calls trade
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
